Poor AstraZeneca. Their pipeline has suffered again after the firm announced that it was dropping an intravenous formulation of AZD7009 for the treatment of atrial fibrillation after disappointing Phase III results.
The drug joins Galida (tesaglitazar) and Exanta (ximelegatran) among recent late-stage product failures at AstraZeneca, and raises pressure on the company to continue to buy in compounds to shore up its R&D portfolio.
No comments:
Post a Comment